<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Osilodrostat: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Osilodrostat: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Osilodrostat: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="127438" href="/d/html/127438.html" rel="external">see "Osilodrostat: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54325675"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Isturisa</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54201563"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cortisol Synthesis Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54285150"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Correct hypokalemia and hypomagnesemia prior to initiating therapy. Obtain baseline ECG; repeat ECG within 1 week after treatment initiation, and as clinically indicated thereafter.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0b58b5af-6bad-40e2-96ee-0f42223a3654">Cushing disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Cushing disease: Oral:</b> Initial: 2 mg twice daily. Titrate by 1 to 2 mg twice daily no more frequently than every 2 weeks according to rate of cortisol changes, tolerability, and clinical response. If patient tolerates a dosage of 10 mg twice daily but cortisol target is not achieved, dosage may be increased by 5 mg twice daily every 2 weeks; typical maintenance dosage: 2 to 7 mg twice daily (maximum: 30 mg twice daily).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54285152"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. In patients with moderate to severe renal impairment, consider using methods other than urinary free cortisol levels to adjust dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31787931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31787931'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F54285153"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Initial: 1 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Initial: 1 mg once daily in the evening.</p></div>
<div class="block dot drugH1Div" id="F55343806"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency: </b>Decrease dose or temporarily interrupt therapy if cortisol drops below target or is rapidly decreasing, or if symptoms of hypocortisolism/adrenal insufficiency occur. May restart at lower dose following normalization of cortisol and resolution of symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia: </b>If hypokalemia persists during therapy despite potassium supplementation, dose reduction or discontinuation of osilodrostat may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>QTc prolongation:</b> Consider temporary discontinuation for QTc interval &gt;480 msec during therapy.</p></div>
<div class="block doe drugH1Div" id="F54285151"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54416570"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Adrenocortical insufficiency/hypocortisolism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat may cause <b>adrenocortical insufficiency</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798','lexi-content-ref-34905500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798','lexi-content-ref-34905500'])">Ref</a></span>), resulting in symptoms of <b>decreased cortisol</b> (eg, <b>abdominal pain</b>, <b>decreased appetite</b>, <b>dizziness</b>, <b>fatigue</b>, <b>nausea</b>, <b>vomiting</b>, <b>hypotension, </b>hypoglycemia). Episodes may resolve with dose reduction, interruption of therapy, and/or corticosteroid treatment when clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798','lexi-content-ref-34905500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798','lexi-content-ref-34905500'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Inhibits cortisol synthesis by inhibition of 11-beta-hydroxylase (CYP11B1), an enzyme needed for the final step of cortisol biosynthesis in the adrenal gland.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most events have been reported during the dose titration period (ie, the first 12 weeks of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798'])">Ref</a></span>); however, may occur at any time during treatment, and cortisol suppression may persist beyond the 4-hour half-life of osilodrostat.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Precipitating causes of decreased cortisol (eg, infection, physical stress)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Androgenic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat may cause <b>altered hormone levels</b>; specific alterations may include increased circulating androgen levels and <b>increased testosterone levels</b>, which may lead to <b>acne vulgaris </b>(in females), <b>hirsutism</b>, and <b>hypertrichosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Inhibits cortisol synthesis by inhibition of 11-beta-hydroxylase (CYP11B1), an enzyme needed for the final step of cortisol biosynthesis. CYP11B1 inhibition is associated with adrenal steroid precursor accumulation and may increase circulating androgen and testosterone levels.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mineralocorticoid effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat may cause increased circulating aldosterone precursor levels, resulting in <b>hypokalemia</b>, <b>hypertension</b>, and <b>edema</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35769081','lexi-content-ref-32730798','lexi-content-ref-34905500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35769081','lexi-content-ref-32730798','lexi-content-ref-34905500'])">Ref</a></span>). Episodes of hypokalemia may require dose reduction, interruption of therapy, and/or treatment (eg, potassium supplements, spironolactone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Inhibits cortisol synthesis and may increase circulating levels of aldosterone precursors (11-deoxycortisol and 11-deoxycorticosterone). Elevated 11-deoxycorticosterone levels may activate mineralocorticoid receptors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increasing osilodrostat C<sub>max</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32730798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32730798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hypokalemia</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat may cause dose-dependent <b>prolonged QT interval on ECG</b>, resulting in cardiac arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35769081','lexi-content-ref-32730798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35769081','lexi-content-ref-32730798'])">Ref</a></span>); maximum mean estimated QTcF increase of up to 5.3 msec with osilodrostat 30 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; QT prolongation was reported progressively over 12 weeks of therapy in one study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35769081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35769081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QT prolongation/torsades de pointes (TdP) (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>); <b>Note</b>: Prescribing information for osilodrostat indicates &gt;480 msec as a potential risk factor.</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or drug interactions that increase serum drug concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54250217"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (7% to 21%), hypertension (10% to 14%), hypotension (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (9% to 11%), skin rash (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (43%), altered hormone level (12%; corticotrophin increased: 14%), decreased cortisol (18% to 31%), hirsutism (10% to 12%), hypokalemia (12% to 17%), increased testosterone level (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13%), decreased appetite (12%), diarrhea (15%), nausea (37%), vomiting (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Benign neoplasm (decrease in pituitary corticotroph tumor volume &gt;20%: 18%), tumor growth (increase in pituitary corticotroph tumor volume &gt;20%: 15%; no correlation between tumor volume and increase in adrenocorticotrophic hormone)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (14%), fatigue (39%), headache (31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (18%), back pain (15%), myalgia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (4%), syncope (2%), tachycardia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (8%), gastroenteritis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (10%), neutropenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (7%), depression (7%), insomnia (8%), malaise (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hypertrichosis (Pivonello 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (Detomas 2022)</p></div>
<div class="block coi drugH1Div" id="F54201480"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F54325676"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isturisa: 1 mg, 5 mg, 10 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F54325674"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54335594"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isturisa Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $198.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $993.79</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F54285154"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered with or without food.</p></div>
<div class="block use drugH1Div" id="F54201479"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cushing disease:</b> Treatment of Cushing disease in adults for whom pituitary surgery is not an option or has not been curative.</p></div>
<div class="block mst drugH1Div" id="F54285130"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Osilodrostat may be confused with orlistat.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54254494"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP2C19 (weak), CYP2D6 (weak), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F54254491"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Osilodrostat.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Osilodrostat. Management: Reduce osilodrostat dose by 50% during coadministration with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F54399912"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of osilodrostat is insufficient to recommend its use for the treatment of Cushing syndrome during pregnancy (ESE [Luger 2021]).</p></div>
<div class="block brc drugH1Div" id="F54399913"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if osilodrostat is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy or for 1 week after the last osilodrostat dose.</p></div>
<div class="block mop drugH1Div" id="F54285156"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">Cortisol levels (initially from at least two 24-hour urine free cortisol collections every 1 to 2 weeks until adequate clinical response is maintained, then at least every 1 to 2 months or as indicated); use caution in interpreting urine free cortisol levels in patients with moderate to severe renal impairment due to reduced urine free cortisol excretion; consider using methods other than urinary free cortisol levels for cortisol monitoring (Braun 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Serum potassium and magnesium (prior to initiation and periodically thereafter); ECG (baseline, after 1 week, and as clinically indicated thereafter); QTc interval (prior to initiation and as clinically indicated thereafter, especially in patients with risk factors for QT prolongation); BP; signs of edema. Signs and symptoms of adrenal insufficiency (eg, anorexia, fatigue, hypoglycemia, hyponatremia, hypotension, nausea, vomiting, weakness); monitor more frequently in patients with hepatic impairment.</p></div>
<div class="block pha drugH1Div" id="F54285135"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Osilodrostat decreases cortisol synthesis via inhibition of 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland.</p></div>
<div class="block phk drugH1Div" id="F54285136"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~100 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 36.4%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatically metabolized by multiple CYP enzymes (eg, CYP3A4, CYP2B6, CYP2D6) and UDP-glucuronosyltransferases to inactive metabolites; no single enzyme contributes &gt;25% to the total clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 90.6% (5.2% as unchanged drug); feces: 1.58%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54245877"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Isturisa</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31787931">
<a name="31787931"></a>Braun LT, Riester A, Oßwald-Kopp A, et al. Toward a diagnostic score in Cushing's syndrome. <i>Front Endocrinol (Lausanne)</i>. 2019;10:766. doi:10.3389/fendo.2019.00766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/31787931/pubmed" id="31787931" target="_blank">31787931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35769081">
<a name="35769081"></a>Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U. Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing's syndrome: results from a single center cohort study. <i>Front Endocrinol (Lausanne)</i>. 2022;13:903545. doi:10.3389/fendo.2022.903545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/35769081/pubmed" id="35769081" target="_blank">35769081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isturisa.2020.03">
<a name="Isturisa.2020.03"></a>Isturisa (osilodrostat) [prescribing information]. Lebanon, NJ: Recordati Rare Disease Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730798">
<a name="32730798"></a>Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. <i>Lancet Diabetes Endocrinol</i>. 2020;8(9):748-761. doi:10.1016/S2213-8587(20)30240-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/32730798/pubmed" id="32730798" target="_blank">32730798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013‐1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34905500">
<a name="34905500"></a>Tabarin A, Haissaguerre M, Lassole H, et al. Efficacy and tolerance of osilodrostat in patients with Cushing's syndrome due to adrenocortical carcinomas. <i>Eur J Endocrinol</i>. 2022;186(2):K1-K4. doi:10.1530/EJE-21-1008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/34905500/pubmed" id="34905500" target="_blank">34905500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation.</i> 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479‐487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381‐390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/osilodrostat-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 127397 Version 65.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
